Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...
XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the ...
Zynlonta and glofitamab show high response and durable remission rates in early r/r DLBCL trial data from ADC Therapeutics, ...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label ...
ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta ...
Shares of ADC Therapeutics fell after it reported the death of two patients in a late-stage trial for treating an aggressive cancer that starts in white blood cells. The stock fell 7.6% to $4.25 in ...
Investing.com -- ADC Therapeutics SA (NYSE:ADCT) stock fell 22% Wednesday after the company released updated data from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with the ...
RWJBarnabas Health's commitment to enhancing access to care includes a transformative partnership with Rutgers University, including the Rutgers Cancer Institute -- the state's only NCI-designated ...
Clinical Trials Arena on MSN
Imugene announces Phase Ib azer-cel efficacy data
"Imugene announces Phase Ib azer-cel efficacy data" was originally created and published by Clinical Trials Arena, a ...
—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and aggressive form of non-Hodgkin lymphoma, with a standard treatment approach typically involving R-CHOP. Despite overall favourable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback